Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 16.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 659,788 shares of the company’s stock after buying an additional 92,933 shares during the period. Northern Trust Corp owned approximately 0.87% of Nurix Therapeutics worth $12,430,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in NRIX. FMR LLC boosted its position in shares of Nurix Therapeutics by 1,711.9% during the fourth quarter. FMR LLC now owns 10,634,231 shares of the company’s stock worth $200,349,000 after buying an additional 10,047,329 shares during the period. Vanguard Group Inc. boosted its position in shares of Nurix Therapeutics by 8.3% during the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company’s stock worth $81,865,000 after buying an additional 333,452 shares during the period. Norges Bank acquired a new position in shares of Nurix Therapeutics during the fourth quarter worth approximately $6,006,000. Nikko Asset Management Americas Inc. boosted its position in shares of Nurix Therapeutics by 42.8% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after buying an additional 236,620 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Nurix Therapeutics by 42.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company’s stock worth $14,869,000 after buying an additional 235,971 shares during the period.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $9.56 on Friday. The stock has a market capitalization of $728.82 million, a P/E ratio of -3.31 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The business’s fifty day moving average is $11.07 and its two-hundred day moving average is $16.91.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the prior year, the company earned ($0.76) earnings per share. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,825 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25. Following the sale, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at $488,660.76. The trade was a 14.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of the business’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now directly owns 61,516 shares in the company, valued at approximately $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,838 shares of company stock valued at $221,500 in the last three months. 7.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on NRIX. JPMorgan Chase & Co. reduced their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Royal Bank of Canada upped their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Morgan Stanley upped their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research report on Monday, February 3rd. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $27.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.44.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.